VERACYTE, INC.·4

Mar 4, 4:16 PM ET

Febbo Phillip G. 4

4 · VERACYTE, INC. · Filed Mar 4, 2026

Insider Transaction Report

Form 4
Period: 2026-03-02
Febbo Phillip G.
Chief Scientific & Med Officer
Transactions
  • Tax Payment

    Common Stock

    [F1]
    2026-03-02$36.01/sh6,035$217,320130,771 total
  • Sale

    Common Stock

    [F2][F3]
    2026-03-02$36.16/sh13,425$485,429117,346 total
Footnotes (3)
  • [F1]Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on March 2, 2026 and does not represent a sale.
  • [F2]The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
  • [F3]Represents weighted average sales price. Sale prices for the transactions range from $35.78 to $36.65. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Signature
/s/ Jonathan Wygant, as attorney-in-fact|2026-03-04

Documents

1 file
  • 4
    wk-form4_1772659004.xmlPrimary

    FORM 4